An integrated global execution platform for cardiovascular MedTech companies.
A structural shift is reshaping how Chinese cardiovascular innovators compete — and where they grow. International markets now represent the most attractive vector for revenue diversification, margin recovery and strategic re-rating.
Global cardiovascular device market compound annual growth rate through 2030.
Annual global interventional cardiovascular spend, expanding into new geographies.
High-priority international markets for Chinese cardiovascular technologies.
China's evolving procurement model is compressing margins across cardiovascular MedTech. The pressure profile, by category — qualitative scale.
National & regional VBP cycles expanding across vascular categories.
Aggressive unit-price cuts in exchange for guaranteed national volume.
Localization incentives reshape competitive dynamics for premium players.
Procurement is evolving to weigh clinical quality, not just lowest price.
Margin compression at home is no longer cyclical — it is structural.
For Chinese cardiovascular MedTech leaders, going global has become a strategic requirement for sustainable growth.
B-Global combines strategic consulting with hands-on execution — across the full GoGlobal value chain.
FDA · CE · NMPA. From strategy to execution across global regulatory pathways.
ISO · MDR · audit readiness. Operational quality, not paperwork.
Distributor strategy, KOLs, sales execution and physician adoption.
Clinical + health economics with fully integrated CRO execution.
Private equity, IPO support and global capital markets connectivity.
We don't just advise — we execute.
Most consulting firms hand the slides over and walk away. We design the strategy and operate it.
Market sizing, sequencing, regulatory pathway design, commercial models. Built on cardiovascular specialization, not generic frameworks.
Registrations, distributor onboarding, study management, commercial rollout. Our teams operate the plan, not just write it.
Performance metrics, accountability and continuous optimization tied to revenue, adoption and reimbursement outcomes.
Structured strategic understanding before execution. Sequenced market priorities. Operational delivery.
Structured understanding before execution.
Not all markets should be approached at the same time.
B-Global operationally executes the plan.
Cross-analysis of market attractiveness, regulatory complexity and investment requirement to define entry tiers.
Few companies combine cardiovascular specialization, commercialization, health economics, CRO execution and global expertise under one roof.
Headquartered in Hong Kong with commercial, regulatory and investment hubs across four continents — a coordinated structure of commercial, regulatory, investment and operational nodes.
A leadership team with decades of cardiovascular MedTech experience across regulatory, commercial, evidence and capital markets.